[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491461":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":59,"collaborators":24,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":24,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":43,"whyStopped":24,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"IRCCS San Raffaele","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","ACTIVE_COMPARATOR","Single fraction radiosurgery on bone metastases (21-24Gy x 1 fraction)",[13],"Radiation: radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm B","Multi-fractioned stereotactic ablative radiotherapy (5 fractions delivered in 5 consecutive working days) with SIB on bone metastases (5Gy x 5 fractions + SIB up to 40-50Gy)",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"RADIATION","radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively","Two protocols of stereotactic ablative radiotherapy, in one vs five fractions ( the later with SIB) are compared",[9,15],null,[26],{"name":27,"affiliation":28,"role":29},"Nadia G Di Muzio, Prof","IRCCS San Raffaele, Milan","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":24,"email":35},"Nadia G Di Muzio, Prof.","CONTACT","+390226437643","dimuzio.nadia@hsr.it",{"name":37,"role":33,"phone":38,"phoneExt":24,"email":39},"Andrei Fodor, MD","+390226437634","fodor.andrei@hsr.it",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"San Raffaele Scientific Institute","RECRUITING","Milan","MI","20132","Italy","IT",{"type":50,"coordinates":51},"Point",[52,53],9.18951,45.46427,{"lat":53,"lon":52},[56,57],{"name":27,"role":33,"phone":34,"phoneExt":24,"email":35},{"name":58,"role":33,"phone":38,"phoneExt":24,"email":39},"Fodor Andrei, M.D.",{"type":29,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Nadia Di Muzio","Professor","100491461","ablative-radiosurgery-vs-stereotactic-rt-in-5-fractions-with-sib-for-oligometastatic-bone-lesions-100491461",false,"NCT05679427","Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions","A Randomised, Prospective, Monoinstitutional Study of Ablative Radiosurgery vs Stereotactic Radiotherapy in 5 Fractions, With Simultaneous Integrated Boost, for the Treatment of Bone Lesions in Oligometastatic Disease","ONES","Inclusion Criteria:\n\n* Performance status ECOG ≤2\n* Life expectancy \\> 6 months according to Mizumoto criteria\\*\n* Oligometastatic disease (Total number of metastases from 1 to 5: both synchronous and metachronous with maximum involvement of three organs in total - lymph nodes, bones, lungs, liver, adrenal gland, brain- with known histology\n* At least one bone metastasis treatable with SABR or SRS\n* Each secondary localization (synchronous, metachronous or oligoprogressive) must be treated with radical intent.\n* Patients may have received other anticancer treatments (surgery for initial site of disease or other metastases, chemotherapy, radiotherapy for other metastatic sites)\n\nExclusion Criteria:\n\n* Sites of disease not eligible for stereotactic radiotherapy\n* Serious medical comorbidities that preclude RT\n* Overlap with a previously treated volume of radiotherapy\n* Dimension greater than 5 cm for extra-cranial lesions.\n* Size greater than 3 cm for brain lesions\n* More than 1 brain metastases\n* Clinical or radiological evidence of spinal cord compression or epidural tumor within 2mm of the spinal cord\n* Radiological evidence of vertebral body fracture or involvement of more than 40% of the vertebral body\n* Radiological evidence of cortical involvement in long bones\n* Pregnant or breastfeeding women","ALL","18 Years","85 Years",{"count":74,"type":75},307,"ESTIMATED","INTERVENTIONAL",[78],"NA","This is a randomised prospective monoinstitutional study comparing radiosurgery at a total dose up to 24 Gy to five fraction stereotactic radiotherapy with simultaneous integrated boost (SIB) up to 50 Gy for the treatment of bone metastases in oligometastatic cancer treated with radical intent. At the end of the first 12 months from the start of the study an interim analysis will be performed taking into account all major endpoints for an initial evaluation of the study , with only an observational purpose, without subsequent protocol changes.",[81],"Oligometastatic Disease",[83,84,81,85],"SBRT","Simultaneous Integrated Boost","Bone Metastases","2025-06-06",{"date":88,"type":89},"2025-06-11","ACTUAL",{"date":91,"type":89},"2022-11-07",{"date":93,"type":75},"2027-12-07",{"name":5,"class":6},1]